Neuronetics (STIM) delivered earnings and revenue surprises of -18.18% and -2.21%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences (NASDAQ: NBIX) delivered a decisive earnings beat in Q3, posting adjusted EPS of $2.17 against ...

Bristol-Myers Squibb has significantly underperformed the broader market over the past year, and analysts are cautious about ...

Our recent deal activity includes announcing the acquisition of Gilgamesh's bretisilocin, expanding our psychiatry pipeline with a next-generation ... The bottom line will continue to expand. This ...

Allschwil, Switzerland – October 30, 2025 Idorsia Ltd (SIX: IDIA), announces 9-month 2025 financial results. Outstanding sales performance of QUVIVIQ coupled with significantly lower operating ...

Pharmaceutical company AbbVie (NYSE:ABBV) reported Q3 CY2025 results , with sales up 9.1% year on year to $15.78 billion. Its ...

CFO and COO Mark Hirschhorn reported, "in the third quarter, we delivered results ahead of expectations for both revenue and adjusted EBITDA, reflecting stronger subscription retention, increased ...

Detailed price information for Avadel Pharmaceuticals Plc ADR (AVDL-Q) from The Globe and Mail including charting and trades.

FY25 revenue consensus $247.79M. Narrows FY25 adjusted EBITDA guidance to ($45M)-($42M) from ($50M)-($45M). Reaffirms AMG visits view 1.3M-1.35M.

Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ (daridorexant) global net sales (excluding sales to partners) increased by >130% year-on-year to CHF 91 million in 9M 2025 - continuing Idorsia's ...

The local rehab center Sierra Tucson has agreed to pay a state fine of $4,000 for failures in caring for its most seriously ill psychiatric patients. In its investigation, the state found that Sierra ...